BROOKLYN PARK, Minn., Feb. 25, 2019 /PRNewswire/ — 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive technologies for structural heart disease, today announced that its AltaValve™, a transcatheter mitral valve replacement (TMVR) technology, will be highlighted in the following presentations at the Cardiovascular Research Technologies (CRT) meeting held March 2-5, 2019 in Washington, DC.
- Sunday, March 3 @ 2:50pm during Percutaneous Mitral Valve Replacement Technology Update Session held in the Omni Shoreham Hotel Blue Ballroom:
– “AltaValve” presented by Philippe Généreux, MD
- Tuesday, March 5 @ 10:50am during CRT Valve & Structural Innovations Session held in the Omni Shoreham Hotel Blue Ballroom:
– “AltaValve: Preserving the Native Mitral Valve” presented by Jeffrey Chambers, MD
Dr. Généreux is Co-Director of the Structural Heart Program at the Gagnon Cardiovascular Institute of Morristown Medical Center (Morristown, NJ).
Dr. Chambers is the Director of the Cardiac Catheterization Lab at Metropolitan Heart and Vascular Institute (Minneapolis, MN). He is also the Founder and Chief Medical Officer of 4C Medical.
About 4C Medical Technologies, Inc.
4C Medical is a medical device company developing minimally invasive technologies for structural heart disease, focusing initially on mitral regurgitation (MR) therapy and subsequently on tricuspid regurgitation therapy. The company’s implant is the first MR treatment with supra-annular positioning and atrial-only fixation. It preserves the native mitral valve and left ventricle, eliminating known issues associated with transcatheter mitral valve replacement technologies which rely on placement and fixation in the native mitral annulus and left ventricle.
For additional information about 4C Medical, please visit its website at www.4CMed.com.
Media Contacts
Robert Thatcher
Chief Executive Officer
(612) 600-8951
rthatcher@4CMed.com
Jim Flaherty
Chief Financial Officer
(612) 599-0650
jflaherty@4CMed.com
SOURCE 4C Medical Technologies, Inc.
